#ES­MO20: Seat­tle Ge­net­ics eyes 4th ap­proval with new da­ta in a crowd­ed field

Does Seat­tle Ge­net­ics have an­oth­er ap­proval on its hands?

The last 12 months, not so great for the world, has been great for Seat­tle Ge­net­ics. The com­pa­ny land­ed two sep­a­rate FDA ap­provals, signed a $4.5 bil­lion deal with Mer­ck and watched an­ti­body-drug con­ju­gates — the tech­nol­o­gy they spent years de­vel­op­ing to broad in­dus­try skep­ti­cism — emerge sud­den­ly as one of the most pop­u­lar ap­proach­es in on­col­o­gy. And on Mon­day at ES­MO, the com­pa­ny and their part­ners at Gen­mab un­veiled the da­ta be­hind the ADC it hopes will pro­vide its next ma­jor FDA ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER